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Abstract (250 words) 1 
Purpose Examine the relationship between the non-medical prescription drug use 2 
(NMPDU) of 6 drug classes and health. 3 
Methods Data from the baseline and follow-up of the Cohort Study on Substance Use 4 
Risk Factors (C-SURF) were used (n = 4,958). Two sets of logistic regression models 5 
were fitted to examine the associations between NMPDU of opioid analgesics, 6 
sedatives/sleeping pills, anxiolytics, antidepressants, beta blockers and stimulants, and 7 
health status (SF-12v2). We first computed odds ratios (ORs) between NMPDU at 8 
baseline and poor mental and physical health at follow-up, adjusting for poor mental or 9 
physical health at baseline. We then computed ORs between poor mental and physical 10 
health at baseline and NMPDU at follow-up, adjusting for NMPDU at baseline. 11 
Results Three key findings regarding mental health were: first, there was a reciprocal 12 
risk between poor mental health and sedatives and anxiolytics; second, poor mental 13 
health increased NMPDU of opioid analgesics and antidepressants, but not vice versa; 14 
and third, there were no associations with stimulants. 15 
Three key findings regarding physical health were: first, poor physical health increased 16 
the risk of NMPDU of anxiolytics; second, the only reciprocal risk was between physical 17 
health and NMPDU of opioid analgesics; and third, there were no associations with 18 
stimulants. 19 
Conclusion These results, among the first ever on reciprocal effects between NMPDU 20 
and mental and physical health status, give unique information concerning the adverse 21 
3 
 
effects of NMPDU on health and vice versa. The study shows that NMPDU is not only a 1 
sign of self-medication, but may induce health problems.  2 
Key words: Longitudinal study, mental health, NMPDU, physical health, Switzerland, 3 
young men 4 
Implications and Contribution (49 words) 5 
This study is among the first to examine the longitudinal association of non-medical 6 
prescription drug use (NMPDU) and poor health status. Findings suggest that there is a 7 
reciprocal risk between NMPDU of sedatives and anxiolytics and poor mental health; 8 
there is no association with stimulants and poor health status. 9 
10 
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1. INTRODUCTION 1 
Prescription drugs such as opioid analgesics, sedatives/sleeping pills, anxiolytics and 2 
stimulants are all considered medically sound and effective in treating a wide range of 3 
disorders (1). However, because of the potential for abusing or becoming dependent on 4 
them (2-5), non-medical prescription drug use (NMPDU) can occur. NMPDU involves 5 
either using a drug without a prescription or in ways not recommended by a doctor (2, 6-6 
8). NMPDU is on the rise in the United States (US) (2, 5), concerns many drug classes 7 
and constitutes a growing public health problem (9). Furthermore, NMPDU of opioid 8 
analgesics is the second most frequent illicit use of drugs, after cannabis (8, 10, 11). In 9 
the US, in 2010, 3.6% of those aged 12 or older were current users of illicit drugs other 10 
than cannabis, with the majority of them non-medical users of psychotherapeutic drugs 11 
(8, 12, 13). Young adults now misuse prescription drugs at higher rates than illegal 12 
drugs with the exception of cannabis (9), and men commonly use drugs more often than 13 
women (14). However, there have been few studies outside the US—particularly few in 14 
Europe and Switzerland (10, 15-17). NMPDU in Switzerland is also a major concern 15 
and, for males, ranks just after alcohol, tobacco and cannabis use (10). The present 16 
study looks at NMPDU and related health issues in Swiss young men from a 17 
longitudinal perspective.  18 
Prescription drugs can increase the risk of psychiatric and other medical disorders (2); 19 
excessive or inappropriate drug use, whether continuous or intermittent, may have 20 
detrimental consequences for the physical or mental health of the consumer/patient 21 
(18). For example, NMPDU of opioids increases the risk of developing opioid-use 22 
disorder (7, 8). It is well known, and unsurprising, that individuals in poor health use 23 
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more medicine (19), but there is also an association between health and substance use 1 
in adolescents who choose to cope with their pressures by abusing both licit and illicit 2 
substances (20). However, little is known about NMPDU. Studies in this field are 3 
commonly cross-sectional and focus on relationships between substance abuse and 4 
health status (21, 22). Few studies have examined the specific associations between 5 
NMPDU and health status, and their cross-sectional design prevented them from 6 
drawing any causal interpretations. Furthermore, the few studies on the relationships 7 
between NMPDU and health status generally focused on NMPDU of opioid analgesics, 8 
benzodiazepines or stimulants alone (8, 13), showing positive associations with pain, 9 
but also with psychiatric disorders (7, 13, 23, 24). However, a longitudinal study by 10 
Martins et al. (8) showed that the association between mood/anxiety disorders and non-11 
medical prescription opioid use could arise in one or more non-mutually exclusive ways: 12 
non-medical prescription opioid use lead to mood/anxiety disorders (the ‘precipitation’ 13 
hypothesis); mood/anxiety disorders lead to non-medical prescription opioid use (the 14 
‘self-medication’ hypothesis); and/or a third factor influences vulnerability to both 15 
(‘shared vulnerability’). The present study looks at NMPDU among twenty-year-old men 16 
in Switzerland. In addition to the commonly studied drug classes, it also looks at the 17 
NMPDU of: 1) beta blockers (which may be misused for their anti-tremor and, perhaps 18 
to a lesser degree, anti-anxiety effects) (25); and 2) antidepressants widely used 19 
against symptoms of depressive disorders and increasingly for anxiety disorders (26). 20 
Moreover, these two substances are among those used by healthy individuals trying to 21 
enhance their cognitive function (e.g. increased concentration and focus) for specific 22 
reasons (e.g. reduce anxiety and fear), particularly students facing exams (17, 27). 23 
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Hence, it would be valuable to know whether and how these two drug classes are 1 
related to mental and physical health.  2 
 3 
To the best of our knowledge, no single longitudinal study has yet examined the 4 
relationships between the NMPDU of six drug classes and physical and mental health in 5 
young men. It thus remains unclear whether all NMPDU induces poor mental and 6 
physical health, or vice versa, whether there is a reciprocal risk association, and what 7 
the nature of the associations might be. The present study investigates the associations 8 
between poor health (i.e. mental and physical) and six NMPDU classes (i.e. opioid 9 
analgesics, sedatives/sleeping pills, anxiolytics, antidepressants, beta blockers and 10 
stimulants) instead of just focusing on the most studied drugs (i.e. opioid analgesics, 11 
benzodiazepines and stimulants). Further, it investigates the bidirectional relationships 12 
between NMPDU and poor mental and physical health using a large sample of young 13 
men in Switzerland.  14 
 15 
 16 
 17 
 18 
 19 
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2. METHODS 1 
2.1. Sample 2 
Data came from the Cohort Study on Substance Use Risk Factors (C-SURF), a 3 
longitudinal study designed to assess substance use patterns among young Swiss men 4 
and the related consequences. Enrolment took place in 3 of 6 national Swiss army 5 
recruitment centers, located in Lausanne (French-speaking), Windisch and Mels 6 
(German-speaking). Including all 6 centers would have proved logistically infeasible 7 
(e.g. including the Italian-speaking center would have required questionnaires in a third 8 
language, despite less than 5% of Swiss speaking Italian; each center required its own 9 
research team for enrolling participants throughout the year; and, for administrative 10 
reasons, the army was unwilling to give access to all its centers, but provide it for the 11 
largest). These 3 centers cover 21 of Switzerland’s 26 cantons, including all French-12 
speaking cantons.  13 
Attending army recruitment is compulsory, so virtually all 20-year-old men in these 14 
regions were eligible for study inclusion. Thus, there were no complex sampling design 15 
features (e.g. related to oversampling of age groups or cantons). It is important to note 16 
that this study was conducted outside any military context. Contrary to most existing 17 
studies on substance use among young adults, whose samples consist essentially of 18 
college students, C-SURF had the unique advantage of enrolling a highly representative 19 
sample of the general population of young Swiss men. Women were not eligible for 20 
inclusion in C-SURF. Because their military recruitment is voluntary, the small number 21 
of women who enroll in the army is not representative of the general female population 22 
in this age group. 23 
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Questionnaires in French or German (see: http://www.c-surf.ch/en/30.html) were sent to 1 
the 7,563 private addresses of those who gave written consent to participate. Baseline 2 
data were collected between September 30th 2010 and March 5th 2012; follow-up data 3 
between January 10th 2012 and April 15th 2013. The baseline and follow-up timeframe 4 
was thus about 15 months. A total of 5,990 participants filled in the baseline 5 
questionnaire; 5,223 (87.2%) filled in the follow-up questionnaire. Missing values were 6 
deleted listwise; the final sample consisted of 4,958 participants (94.9% of the follow-up 7 
sample). As shown in the study of Studer et al., there was a certain amount of non-8 
response bias, but this was often small and went in different directions. For the 9 
Francophone sample, for example, there were more alcohol abstainers among non-10 
respondents (11.6%) than respondents (11.2%), but there were more non-smokers 11 
(63.4%) among respondents than non-respondents (49.8%), and this was found for 12 
cannabis non-users too (respondents, 64.8%; non-respondents, 58.0%) (28). To 13 
analyse non-response bias, a short, five-minute questionnaire containing questions on 14 
demography, alcohol, tobacco and cannabis use was administered to all conscripts in 15 
the recruitment process, yielding a response rate of 94%. Unfortunately, the brevity 16 
necessary to ensure a high response rate from non-participants in the cohort study 17 
meant that no questions about NMPDU were asked in this short questionnaire. Given 18 
the small differences for the others drugs assessed, we did not expect a major non-19 
response bias for NMPDU (28, 29). 20 
The study protocol (Protocol No 15/07) was approved by Lausanne University Medical 21 
School’s Clinical Research Ethics Committee. 22 
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2.2. Measurements 1 
2.2.1. NMPDU 2 
NMPDU was described to participants as use of prescription drugs without a 3 
prescription or in ways not recommended by a doctor. 4 
Both the baseline and follow-up questionnaires assessed the frequency of NMPDU for 6 5 
drug classes (opioid analgesics, sedatives/sleeping pills, anxiolytics, antidepressants, 6 
beta blockers and stimulants) over the last 12 months. Examples were given for each 7 
class: a) sedatives/sleeping pills (e.g. benzodiazepines like Dalmadorm® or Rohypnol®; 8 
zopiclone or zolpidem like Imovane® or Stilnox®; chloral hydrate; barbiturates); b) 9 
anxiolytics (e.g. benzodiazepines like Valium®, Xanax®, Librax®; muscle relaxants); c) 10 
opioid analgesics excluding aspirin and paracetamol (e.g. codeine, Benylin®; opiates 11 
like fentanyl, hydrocodone; buprenorphine like Tamgesic®); d) antidepressants (e.g. 12 
Fluoxetine®, Remeron®); e) stimulants (e.g. amphetamine sulfate, atomoxetine or 13 
methylphenidate); and f) beta blockers (e.g. propranolol, atenolol or metoprolol). The 14 
frequency of NMPDU was dichotomized as ‘use’/‘no use’ over the past 12 months. 15 
NMPDU prevalence was first calculated for any use (i.e. use of at least one class at 16 
least once in the past 12 months) and then separately for each of the 6 drug classes.  17 
2.2.2. Health Status 18 
Health was assessed using the ‘Medical Outcomes Study 12-Item Short Form Survey 19 
Instrument’ (SF-12 v2)(30). This is a multipurpose, short form survey with 12 questions, 20 
all selected from the SF-36 Health Survey (31). The SF-12 is a generic measure and 21 
does not target a specific age or disease group. It was developed to provide a shorter, 22 
10 
 
yet valid alternative to the SF-36, and is weighted and summed to provide easily 1 
interpretable scales for physical and mental health. Its scoring guidelines allow two 2 
summary scores to be derived: the ‘physical health summary’ score and the ‘mental 3 
health summary’ score. These range from 0 to 100 and are computed using the scores 4 
from 12 questions; zero and 100 indicate the lowest and highest levels of health 5 
measured by the scale, respectively. Linear transformations were performed to obtain 6 
norm-based scores (mean = 50; SD = 10). Due to the non-normal distribution of these 7 
standardized summary scores, we dichotomized them into ‘good health’ ( ≥ 45, coded 8 
‘0’) and ‘poor health’ ( < 45, coded ‘1’) based upon clinical meaningfulness (32, 33) 9 
defining ½ a standard deviation (SD; i.e. 5).  10 
2.2.3. Covariates 11 
Demographic covariates included: age; alcohol use with binge drinking classed as 12 
frequency of 6 drinks or more (non binge drinking coded ‘0’; binge drinking coded ‘1’); 13 
tobacco (less than daily smoking coded ‘0’; daily smoking coded ‘1’); cannabis (used 14 
once a week or less, i.e. non-hazardous cannabis use, coded ‘0’; twice weekly use or 15 
more, i.e. hazardous cannabis use, coded ‘1’); marital status (coded ‘single/divorced’ or 16 
‘married/couple’); educational level ( < 10 years of schooling, coded ‘primary’; 10–12 17 
years, coded ‘secondary’; 13 years or more, coded ‘tertiary’); and current living 18 
arrangements (coded ‘living in a family/couple’ or ‘living alone/orphanage/foster 19 
home/homeless’). 20 
2.3. Statistical analyses 21 
All analyses were performed using Stata software, version 12. Analyses included 22 
descriptive demographic characteristics of the sample, followed by logistic regression 23 
11 
 
models to assess: 1) associations between any and specific NMPDU at baseline and 1 
poor health (separately for mental and physical health) at follow-up; and 2) associations 2 
between poor health (separately for mental and physical health) at baseline and any 3 
and specific NMPDU at follow up. 4 
To examine the causal effects of NMPDU on poor mental and physical health, two sets 5 
of models were fitted. Odds ratios (ORs) were computed between NMPDU at baseline 6 
and poor mental and physical health at follow-up, adjusting for poor mental or physical 7 
health at baseline and for the other covariates. All participants with poor mental or 8 
physical health at baseline were then excluded in order to establish the causal 9 
relationship between NMPDU at baseline and the incidence of poor mental or physical 10 
health at follow-up. Accordingly, 1,265 participants in poor mental health at baseline 11 
were excluded (N = 3,693) from the models predicting poor mental health at follow-up, 12 
and 247 participants in poor physical health at baseline were excluded (N = 4,711) from 13 
the models predicting poor physical health at follow-up. The rates for any NMPDU 14 
between those excluded and those who participated did not vary.   15 
Two sets of models were also fitted to examine the causal effects of poor mental and 16 
physical health on NMPDU. ORs between poor mental or physical health at baseline 17 
and NMPDU at follow-up were estimated, adjusting for NMPDU at baseline and for the 18 
other covariates. In order to establish any causal relationships between mental/physical 19 
health at baseline and incidence of NMPDU at follow up, the models were fitted again, 20 
excluding all participants with NMPDU at baseline. NMPDU of each drug class and of 21 
any NMPDU (i.e. the use of at least one class) were assessed, respectively. All 22 
analyses were made separately for mental and physical health.    23 
12 
 
In order to carry out a sensitivity analysis, all these calculations were repeated using the 1 
continuous scores. Those results tended towards the same conclusions; however we 2 
choose to use dichotomized variables for clearer clinical meanings. 3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
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3. RESULTS 1 
The mean age of participants was 19.96 ± 1.19 years at baseline and 21.25 ± 1.21 2 
years at follow-up, i.e. about 15 months difference.  3 
Table 1 presents the distribution of the baseline cohort according to the measures 4 
analyzed. The majority of participants declared no NMPDU (89.49%, thus prevalence of 5 
any use was 10.51%). The most prevalent NMPDU reported by these young adults 6 
were for opioid analgesics (6.53%), sedatives/sleeping pills (2.88%) and anxiolytics 7 
(2.56%). 8 
A total of 25.51% had poor mental health and 4.98% had poor physical health. 9 
Insert Table 1 about here 10 
Examining the effects of NMPDU at baseline on poor health status at follow-up, after 11 
adjustment (Table 2), the only positive and significant relationships were for any 12 
NMPDU, sedatives/sleeping pills and anxiolytics, with adjusted ORs (AORs) of 1.26 13 
[1.03–1.54], 1.45 [1.01–2.08], and 1.52 [1.04–2.24], respectively. After excluding 14 
participants with poor mental health at baseline, NMPDU of anxiolytics and beta 15 
blockers at baseline was significantly associated with an increased risk of poor mental 16 
health (AORs were 2.11 [1.25–3.56] and 2.97 [1.04–8.51], respectively). Generally, 17 
NMPDU at baseline increased the risk of poor mental health at follow-up, even if the 18 
association was not always significant. 19 
Concerning poor physical health, a positive and significant association with the NMPDU 20 
of opioid analgesics was only observed in the adjusted model; AOR was 1.55 [1.00–21 
14 
 
2.42] in the adjusted model. Generally, NMPDU at baseline did not increase the risk of 1 
poor mental health at follow-up. 2 
Insert Table 2 about here 3 
The effects of poor mental health status at baseline was significantly and positively 4 
related to any NMPDU and to 4 classes of NMPDU at follow-up, but not to stimulant and 5 
beta blocker use (Table 3). Results remained the same in both the adjusted model and 6 
after excluding participants with NMPDU at baseline. There was a reciprocal risk 7 
between poor mental health and anxiolytics and sedatives/sleeping pills; opioid 8 
analgesics, antidepressants and beta blockers showed a unidirectional association; and 9 
there was no association between poor mental health and stimulants. 10 
In the adjusted model, the only significant and positive associations between poor 11 
physical health at baseline and NMPDU at follow-up, were with the NMPDU of opioid 12 
analgesics and anxiolytics; AORs were 1.82 [1.18–2.81] and 2.10 [1.07–3.77], 13 
respectively. Excluding NMPD users at baseline, the AOR between poor physical health 14 
at baseline and NMPDU incidence was significant for all classes of NMPDU except for 15 
any NMPDU and stimulants. Therefore, the only reciprocal risk was between poor 16 
physical health and NMPDU of opioid analgesics; poor physical health increased the 17 
risk of almost all incidences of NMPDU. 18 
Insert Table 3 about here 19 
These analyses were repeated with continuous instead of dichotomous health scores; 20 
the direction and size of effects remained basically the same. 21 
 22 
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4. DISCUSSION 1 
This study finds a clear association between NMPDU and health status. However, the 2 
associations between NMPDU and health status arise in one or more non-mutually 3 
exclusive ways. 4 
Poor mental health 5 
For the association of NMPDU and poor mental health, there are 3 key findings. First, 6 
no association was found between poor mental health and NMPDU of stimulants.  7 
Second, there were 2 unidirectional associations: poor mental health increased NMPDU 8 
of opioid analgesics and antidepressants. The finding that poor mental health increased 9 
NMPDU of opioid analgesics is consistent with Zullig et al.‘s cross-sectional study(13) 10 
and with the self-medication hypothesis in Martins et al.‘s study(8). In this hypothesis, 11 
NMPDU occurs after mental health problems have occurred, i.e. individuals with poor 12 
mental health engage in NMPDU to relieve their symptoms (8). The fact that poor 13 
mental health increased NMPDU of antidepressants can also be interpreted as self-14 
medication, but this is only speculation. Therefore, developing prevention strategies 15 
about self-medication and its consequences on mental health problems are important.  16 
Third, there were reciprocal associations between any NMPDU, NMPDU of 17 
sedatives/sleeping pills and NMPDU of anxiolytics, and poor mental health. This 18 
suggests that NMPDU of sedatives/sleeping pills and anxiolytics at baseline increased 19 
the risk of poor mental health at follow-up, and vice versa. We can interpret this to mean 20 
that NMPDU occurs not only to self-medicate poor mental health, but that NMPDU for 21 
other reasons may lead to poor mental health. Although not all associations remained 22 
16 
 
significant, this interpretation is bolstered by the fact that the strength of associations 1 
remained consistent even after excluding men with poor mental health at baseline. 2 
Comparisons with earlier findings are difficult. To our knowledge, this is the first study 3 
published using prospective data to examine reciprocal effects between NMPDU for 6 4 
different classes of drugs and health status. Our findings show that NMPDU is a 5 
predictor of poor mental health; this is consistent with the fact that illicit drug 6 
use/NMPDU is widely thought to have a negative effect on health status in general (21, 7 
34). They also confirm previous studies indicating that poor health is a predictor of (both 8 
any and specific) NMPDU (7, 35-37).  9 
The present study’s findings suggested that young men in poor health may self-10 
medicate, and those declaring NMPDU may worsen their health status over time due to 11 
side effects (from the frequencies or quantities of drugs taken). Confirming these results 12 
will require future studies to look at usage frequencies, quantities taken and motives for 13 
NMPDU. The present study’s data failed to demonstrate that the NMPDU of stimulants 14 
was associated with poor mental health and vice versa. However, the lack of their 15 
effects on health may result from the lower prevalence rates of NMPDU of stimulants in 16 
this study. It is possible that men with mental health problems do not self-medicate 17 
using stimulants, because this may make them even more restless and uneasy. It is 18 
notable that, besides antidepressants, other drug classes were more ‘downers’ than 19 
‘uppers’. It is possible that people receiving stimulants in stimulant treatment do not use 20 
them non-medically. Finally, it may be that stimulants used as drugs for their perceived 21 
effects are easily accessible on the illicit drug market; hence, due to much lower 22 
stimulant doses, and thus weaker effects, NMPDU may just not be as attractive as is in 23 
17 
 
the US. However, we can only speculate about this finding. Due to inconclusive data on 1 
this issue, further research will be needed to confirm these results. 2 
Poor physical health 3 
For the association of NMPDU and poor physical health, there are 3 key findings. First, 4 
poor physical health at baseline increased the risk of NMPDU of anxiolytics at follow-up, 5 
but not vice versa. Second, only NMPDU of opioid analgesics and poor physical health 6 
showed reciprocal risk. Third, there was no association between poor physical health 7 
and the NMPDU of stimulants. Results showing that poor physical health may be a 8 
precursor for NMPDU are consistent with Simoni-Wastila et al.‘s study (38). This is 9 
explained by the self-medication hypothesis: it is well known that people self-medicate 10 
when they are not well. For example, studies have shown positive associations between 11 
NMPDU of opioids and pain (7, 23). Stogner and Gibson (20) described a link between 12 
illicit drugs and health problems that is consistent with our results; we also found a link 13 
between NMPDU and physical health problems. We suggest that regardless of the kind 14 
of drug used, there is a link with physical health. 15 
Generally, the mechanisms which influence adolescent medicinal drug use are not well 16 
understood, but our findings suggested that self-medication as a coping strategy may 17 
be an important factor, i.e. a response to internal or external strain.  18 
Limitations 19 
This study had some limitations. First, study data were self-reported. Although self-20 
reported data on risky behaviors and substance use are generally considered valid (39), 21 
self-reported surveys could introduce various forms of bias, including recall bias, 22 
18 
 
pressure to give desirable answers and non-response bias. Second, this study’s sample 1 
inclusion criteria meant it comprised only men. Therefore generalizations about health 2 
status and NMPDU for women cannot be made, although they are known to misuse 3 
prescriptions drugs too.  4 
Finally, we did not use diagnostic criteria to classify men’s mental health, but a self-5 
reported screening tool, which might explain the rather low poor mental and physical 6 
health prevalence rates obtained. 7 
Conclusion 8 
Due to the lack of longitudinal studies on this topic, this study provides unique 9 
information about the mental and physical health status of respondents declaring 10 
NMPDU for 6 different classes of drugs. To our knowledge, this is the first time that 11 
these relationships have been described in the same study. Our findings showed that 12 
NMPDU of most classes of drugs were linked with health status (both mental and 13 
physical), however no association was found with NMPDU of stimulants. These results 14 
could help address prevention strategies to young adults about the growing public 15 
health problem of NMPDU. 16 
 17 
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Table 1: Descriptive data of independent and dependent variables (N = 4,958) 4 
Baseline 
variables 
  
 
n (%) 
    Educational level  
  Primary (<10 years) 2,421 (48.83) 
 Secondary (10–12 years) 1,224 (24.69) 
 Tertiary (13 years or more) 1,313 (26.48) 
 Relationship status 
  Single/divorced 4,720 (95.20) 
 Married/couple 238 (4.80) 
 Current living arrangements 
  Family/couple 4,793(96.67) 
 Other (alone/orphanage/foster 
home/homeless) 167 (3.33) 
 Physical health 
  Poor 247 (4.98) 
 Good 4,711 (95.02) 
 Mental health 
  Poor 1,265 (25.51) 
 Good 3,693 (74.49) 
 Non-medical prescription 
drugs use 
  Yes 521 (10.51) 
 No  4,437 (89.51) 
 Class of drugs 
  Opioid analgesics  324 (6.53) 
 Sedatives/sleeping pills  143 (2.88) 
 Anxiolytics  127 (2.56) 
 Stimulants  93 (1.88) 
 Antidepressants  43 (0.87) 
 Beta blockers  24 (0.48) 
 
23 
 
Table 2: Multiple logistic regression using NMPDU at baseline to predict mental and physical health at follow-up.  
 
 
 
 
 
 
 
 
 
 
 
 
 
1: adjusted for poor mental or physical health at baseline, age, alcohol, tobacco, cannabis, relationship status, educational level, current living 
arrangements and financial independence, *p < .05. 
2: adjusted for age, alcohol, tobacco, cannabis, relationship status, educational level, current living arrangements and financial independence, 
*p < .05. 
BS, baseline study; NMPDU, non-medical prescription drug use; AOR, adjusted OR  
PREDICTOR 
NMPDU 
Baseline 
DEPENDENT 
      Mental Health Follow-up                       Physical Health  Follow-up       
 
AOR1(N=4,958) 
AOR2(excluding 
participants in 
poor mental 
health at BS) 
N=3,693 AOR1(N=4,958) 
AOR2(excluding 
participants in 
poor physical 
health at BS) 
N=4,711 
Any NMPDU 1.26 (1.03-1.54)* 1.26 (0.98-1.64) 1.36 (0.93-2.00) 1.29 (0.83-2.00) 
Opioid analgesics  1.07 (0.84-1.38) 1.06 (0.77-1.47) 1.55 (1.00-2.42)* 1.62 (0.99-2.66) 
Sedatives/sleeping 
pills  1.45 (1.01-2.08)* 1.51 (0.91-2.50) 1.57 (0.83-2.97) 1.75 (0.87-3.53) 
Anxiolytics  1.52 (1.04-2.24)* 2.11 (1.25-3.56)* 1.34 (0.67-2.71) 0.90 (0.32-2.49) 
Stimulants  1.18 (0.75-1.84) 1.16 (0.62-2.15) 1.18 (0.52-2.69) 1.11 (0.40-3.12) 
Antidepressants  1.56 (0.81-3.01) 2.53 (0.87-7.38) 0.24 (0.03-1.85) 0.58 (0.08-4.31) 
Beta blockers  1.93 (0.82-4.57) 2.97 (1.04-8.51)* 0.61 (0.07-4.71) 1.40 (0.18-10.68) 
24 
 
Table 3: Multiple logistic regression using mental and physical Health at baseline to predict NMPDU at follow up.  
    
DEPENDENT 
NMPDU 
Follow-up       
    
PREDICTOR 
 
Any NMPDU 
Opioid 
analgesics  
Sedatives/ 
sleeping pills  Anxiolytics  Stimulants  Antidepressants  Beta blockers  
Mental 
Heath Baseline 
 
AOR1 
(N=4,958) 
1.88  
(1.53-2.31)** 
1.82  
(1.42-2.35)** 
2.02  
(1.41-2.91)** 
2.25  
(1.53-3.33)** 
1.37  
(0.84-2.24) 
3.73  
(2.13-6.52)** 
2.06  
(0.95-4.45) 
 
AOR2 
(excluding 
participants 
using 
NMPD at 
BS)  
n=4,437  
1.79  
(1.39-2.30)** 
n=4,634  
1.69  
(1.26-2.27)** 
n=4,815  
1.97  
(1.30-2.97)** 
n=4,831 
2.63  
(1.71-4.05)** 
n=4,865  
1.10  
(0.60-2.01) 
n=4,915  
3.74 ( 
2.07-6.77)** 
n=4,769  
2.02  
(0.88-4.61 
   
 NMPDU 
Follow-up 
   
  
Any 
NMPDU 
Opioid 
analgesics  
Sedatives/ 
sleeping pills  Anxiolytics  Stimulants  Antidepressants  Beta blockers  
 Physical 
health 
Baseline 
AOR1 
(N=4,958) 
1.32  
(0.88-1.97) 
1.82  
(1.18-2.81)** 
1.33  
(0.69-2.59) 
2.01  
(1.07-3.77)* 
0.86  
(0.33-2.24) 
1.95  
(0.84-4.54) 
2.12 
(0.69-6.54) 
 
 
AOR2 
(excluding 
participants 
using NMPD 
at BS)  
n=4,437 
1.50  
(0.93-2.40) 
n=4,634  
2.10  
(1.29-3.41)** 
n=4,815  
2.01  
(1.03-3.95)* 
n=4,831  
2.54  
(1.28-5.01)** 
n=4,865 
1.10  
(0.33-3.59) 
n=4,915 
 3.25 
(1.42-7.41)** 
n=4,769  
3.48  
(1.16-10.43)* 
 1: adjusted for poor mental or physical health at baseline, age, alcohol, tobacco, cannabis, relationship status, educational level, current living 
arrangement and financial independence, *p < .05, **p ≤ .001 
2: adjusted for age, alcohol, tobacco, cannabis, relationship status, educational level, current living arrangement and financial independence,  
*p < .05, **p ≤ .001  
BS, baseline study; NMPDU, non-medical prescription drug use; AOR, adjusted OR 
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